- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 417
MDMetrix jots down $3m
Seattle Children’s EHR management software publisher MDMetrix has now raised $4m in all following a seed round backed by the investment arm of Washington Research Foundation.
May 16, 2019Locate Bio locks down $2.6m
The additional cash will allow University of Nottingham biomedicine spinout Locate Bio to advance two internal programs and support its collaborations with external partners.
May 16, 2019Clevertar clutches onto $275,000
The board at Flinders University-founded medical avatar software platform Clevertar has agreed to pump in funding to clear the spinout's outstanding liabilities to creditors including the university.
May 16, 2019Icometrix processes $18m
Icometrix developers brain imaging technology based on KU Leuven and University of Antwerp research to help assess conditions such as Alzheimer’s disease.
May 16, 2019Phathom scares up $90m
Phathom Pharmaceuticals has been launched with $140m in debt and equity financing to commercialise a gastrointestinal disease drug licensed from Takeda.
May 16, 2019Kevrekian seizes CVS Health promotion
Gregor Kevrekian, previously senior director of CVS Health’s corporate development and venture investing business, has ascended to executive director.
May 16, 2019NextStep Robotics drills $600,000
NextStep Robotics, which last raised funding in February 2018, is commercialising research from two University of Maryland campuses and the Baltimore Veterans Affairs Motor Performance Laboratory.
May 15, 2019Healthineers prompts Siemens' Pompl to new role
René Pompl, formerly principal at Siemens’ Next47, has joined the corporate’s medical-focused Healthineers division as manager of venture technology.
May 15, 2019TreeFrog leaps into $7.8m series A
Satt Aquitaine-founded TreeFrog has now raised $11.1m in equity and grant funding, having secured follow-on contributions from investors including the tech transfer office.
May 14, 2019Axcella accepts public listing
Metabolic therapy developer Axcella Health has priced its shares at $20 each in an offering that enabled Nestlé Health Science to exit.
May 14, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


